Pharma

Karo Pharma Publishes the 2019 Annual Report

Wednesday, April 1, 2020 - 2:26pm

HUDDINGE, Sweden, April 1, 2020 /PRNewswire/ -- Today, on 1 April 2020, Karo Pharma is publishing its annual report for 2019 on the company's website, www.karopharma.com .

Key Points: 
  • HUDDINGE, Sweden, April 1, 2020 /PRNewswire/ -- Today, on 1 April 2020, Karo Pharma is publishing its annual report for 2019 on the company's website, www.karopharma.com .
  • Karo Pharma specialises in the sales and marketing of prescription drugs and over the counter products for everyday healthcare.
  • Karo Pharma is headquartered in Stockholm, Sweden, and quoted on Nasdaq Stockholm Mid Cap.
  • This information is information that Karo Pharma is obliged to make public pursuant to the Swedish Securities Market Act.

Yuyu Pharma introduces new advanced ERP management system

Tuesday, March 31, 2020 - 9:00am

SEOUL, South Korea, March 31, 2020 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX 000220) introduced a new Enterprise Resource Planning (ERP) system to identify real-time management conditions and enhance system management for more efficient decision-making.

Key Points: 
  • SEOUL, South Korea, March 31, 2020 /PRNewswire/ -- Yuyu Pharma (CEO Robert Wonsang Yu, KRX 000220) introduced a new Enterprise Resource Planning (ERP) system to identify real-time management conditions and enhance system management for more efficient decision-making.
  • The focus was integrating the ERP systems of not only Yuyu Pharma, but with those of Yuyu's affiliates such as Yuyu Teijin Medicare.
  • "The ERP system allows for more insightful and secure methods for data management.
  • Currently, Yuyu Pharma is focusing on developing new drugs for treating enlarged prostates and dry eye syndrome.

RAMM Pharma Corp. Announces Postponement of Filing of Interim Financial Statements

Monday, March 30, 2020 - 2:36pm

The Company expects to report results within the next two weeks, and is afforded a postponement up to a maximum 45-day extension pursuant to blanket relief for all market participants granted by the Canadian Securities Administrators.

Key Points: 
  • The Company expects to report results within the next two weeks, and is afforded a postponement up to a maximum 45-day extension pursuant to blanket relief for all market participants granted by the Canadian Securities Administrators.
  • Other than disclosed in the Companys press releases and its issuer profile on SEDAR, there have not been any material business developments since the date of the last annual financial statements of the Company that were filed.
  • Founded in 1988 in Montevideo, Uruguay, the Company is a well established pharmaceutical and medical product business that has developed medically registered and approved plant-derived cannabinoid pharmaceutical products.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA and Ramm Pharma Holdings Corp.

C² PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment

Thursday, March 26, 2020 - 10:40pm

(C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin.

Key Points: 
  • (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin.
  • In early March, the API was listed for its potential to reduce the symptoms of COVID-19 patients in combination with other anti-viral drugs based on initial research in South Korea and India1.
  • As the leading manufacturer of Digoxin API for the pharmaceutical industry, C2 PHARMA holds safety stocks to ensure supply as a standard operating procedure.
  • R&D-scale contract synthesis services, analytical services, phytochemical profiling and impurity manufacturing are provided via affiliate company ASM Research Chemicals .

C² PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19 Combination Treatment

Thursday, March 26, 2020 - 10:30pm

(C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin.

Key Points: 
  • (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, is announcing that they will open access to safety stocks of the active pharmaceutical ingredient (API), Digoxin.
  • In early March, the API was listed for its potential to reduce the symptoms of COVID-19 patients in combination with other anti-viral drugs based on initial research in South Korea and India1.
  • As the leading manufacturer of Digoxin API for the pharmaceutical industry, C2 PHARMA holds safety stocks to ensure supply as a standard operating procedure.
  • R&D-scale contract synthesis services, analytical services, phytochemical profiling and impurity manufacturing are provided via affiliate company ASM Research Chemicals .

RAMM Pharma Corp. Receives Federal Approval and Registration of XALEX™ 10 (cannabidiol) Oral Solution

Thursday, March 26, 2020 - 6:02pm

The approval of XALEX 10 is a significant accomplishment for RAMM Pharma, offering patients another federally approved pharmaceutical CBD medicine, stated Jack Burnett, Chief Executive Officer.

Key Points: 
  • The approval of XALEX 10 is a significant accomplishment for RAMM Pharma, offering patients another federally approved pharmaceutical CBD medicine, stated Jack Burnett, Chief Executive Officer.
  • XALEX 10 is a 10% plant-derived pharmaceutical formulation of pure CBD approved by the MSP as an anti-epileptic medication for the treatment of seizures associated with refractory epilepsy.
  • The rigorous MSP approval process includes stability testing standards which conform to international pharmaceutical requirements for registered pharmaceutical products.
  • RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA and Ramm Pharma Holdings Corp.

COVID-19 Shutdowns in China: Infiniti Research Explains What This Means for the Global Pharmaceutical Supply Chain

Friday, March 20, 2020 - 1:30pm

Our global industry specialist teams ensure the international consistency of our research, enabling powerful access to the real story behind consumer change.

Key Points: 
  • Our global industry specialist teams ensure the international consistency of our research, enabling powerful access to the real story behind consumer change.
  • (Graphic: Business Wire)
    Pharma manufacturing companies across the globe are heavily dependent on active pharmaceutical ingredients (APIs) from China.
  • Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges.
  • Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies.

SciBite Announced as Fastest-growing Company in Pharma Fast 50

Wednesday, March 18, 2020 - 11:01am

CAMBRIDGE, England, March 18, 2020 /PRNewswire/ -- SciBite today announced being named the fastest-growing company identified in this year's Alantra Pharma Fast 50, an annual ranking of privately-owned pharmaceutical businesses in the UK based on growth speed.

Key Points: 
  • CAMBRIDGE, England, March 18, 2020 /PRNewswire/ -- SciBite today announced being named the fastest-growing company identified in this year's Alantra Pharma Fast 50, an annual ranking of privately-owned pharmaceutical businesses in the UK based on growth speed.
  • Securing contracts with three-quarters of the world's largest pharma companies, SciBite topped the chart having delivered compound annualised growth of 76% over the past two years, and now boasts a workforce of 50+ scientific experts servicing more than 50 clients worldwide.
  • You can also keep up-to-datewith SciBite's monthly webinars: https://www.scibite.com/events/
    Read more about SciBite's Pharma Fast 50 win: https://scibite.info/PharmaFast50
    SciBite provides an enterprise-ready semantic software infrastructure to standardise and transform scientific information silos into clean, interoperable data.
  • Supporting the top 20 pharma with use cases across life sciences, SciBite is headquartered in the UK with additional sites in the US and Japan.

Ergomed Announces Provision of Clinical Research Services for COVID-19 Clinical Study

Wednesday, March 18, 2020 - 11:00am

The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).

Key Points: 
  • The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).
  • Ergomed is providing clinical research services for the study and has been integrally involved in the design and implementation of the study from a clinical and operational perspective.
  • Ergomed is proud to be making a contribution to this effort by bringing our proven capabilities and expertise to bear on this important study.
  • Ergomed plc (LSE: ERGO), a company focused on providing specialized services to the pharmaceutical industry, is providing clinical research services for the study.

SciBite Announced as Fastest-growing Company in Pharma Fast 50

Wednesday, March 18, 2020 - 7:01am

CAMBRIDGE, England, March 18, 2020 /PRNewswire/ -- SciBite today announced being named the fastest-growing company identified in this year's Alantra Pharma Fast 50, an annual ranking of privately-owned pharmaceutical businesses in the UK based on growth speed.

Key Points: 
  • CAMBRIDGE, England, March 18, 2020 /PRNewswire/ -- SciBite today announced being named the fastest-growing company identified in this year's Alantra Pharma Fast 50, an annual ranking of privately-owned pharmaceutical businesses in the UK based on growth speed.
  • Securing contracts with three-quarters of the world's largest pharma companies, SciBite topped the chart having delivered compound annualised growth of 76% over the past two years, and now boasts a workforce of 50+ scientific experts servicing more than 50 clients worldwide.
  • You can also keep up-to-datewith SciBite's monthly webinars: https://www.scibite.com/events/
    Read more about SciBite's Pharma Fast 50 win: https://scibite.info/PharmaFast50
    SciBite provides an enterprise-ready semantic software infrastructure to standardise and transform scientific information silos into clean, interoperable data.
  • Supporting the top 20 pharma with use cases across life sciences, SciBite is headquartered in the UK with additional sites in the US and Japan.